Further boosting the pipeline, mid-stage drugs like Sanofi/Regeneron’s itepekimab, AstraZeneca’s benralizumab, Amgen Inc ...

Patients with asthma who switched biologics multiple times were younger, more likely to identify as Black, and had more ...

The new treatment will be a competitor of GSK’s Nucala (mepolizumab), which was approved in 2018 as the first targeted ...

The CHMP’s recommendation is based on results from the MANDARA phase 3 trial, which compared efficacy and safety of benralizumab vs mepolizumab, the only approved treatment for EGPA, in patients ...

New indication supported by the MANDARA trial, which showed nearly 60% of patients achieved remission and 41% of patients fully stopped taking oral corticosteroidsAstraZeneca’s Fasenra (benralizumab) ...

Cambridge: AstraZeneca has announced that Fasenra (benralizumab) has been approved in the European Union (EU) as an add-on treatment for adult patients with relapsing or refractory ...

A solid showing for HIV drugs sold by majority-owned ViiV Healthcare and speciality medicines like cancer therapies Zejula ...

Fasenra is the second biologic approved for the condition. The decision follows a positive opinion from the Committee for ...

The antibody is a follow-up to the company's once-monthly IL-5 inhibitor Nucala (mepolizumab), which has been on the market since 2015. Nucala is approved for four indications, namely severe ...

Two posters presented at the CHEST 2024 annual meeting showed that mepolizumab significantly reduces exacerbations in patients with severe asthma and asthma with concurrent chronic obstructive ...

2020). Primary Objective To evaluate the influence of poor ICS adherence on response to mepolizumab treatment in patients with severe eosinophilic asthma. Methods This was a retrospective study that ...